Arvinas, Inc. (ARVN)

NASDAQ: ARVN · IEX Real-Time Price · USD
44.49
-1.06 (-2.33%)
Sep 30, 2022 4:00 PM EDT - Market closed
-2.33%
Market Cap 2.37B
Revenue (ttm) 91.12M
Net Income (ttm) -233.15M
Shares Out 53.21M
EPS (ttm) -4.18
PE Ratio n/a
Forward PE 17.70
Dividend n/a
Ex-Dividend Date n/a
Volume 355,313
Open 44.77
Previous Close 45.55
Day's Range 44.25 - 46.68
52-Week Range 34.90 - 97.33
Beta 2.06
Analysts Buy
Price Target 93.13 (+109.3%)
Earnings Date Nov 1, 2022

About ARVN

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patient... [Read more...]

Industry Pharmaceuticals
IPO Date Sep 27, 2018
Employees 280
Stock Exchange NASDAQ
Ticker Symbol ARVN
Full Company Profile

Financial Performance

In 2021, Arvinas's revenue was $46.70 million, an increase of 114.22% compared to the previous year's $21.80 million. Losses were -$191.00 million, 60.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 26 analysts, the average rating for ARVN stock is "Buy." The 12-month stock price forecast is 93.13, which is an increase of 109.33% from the latest price.

Price Target
$93.13
(109.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arvinas Gives Back to Local Greater New Haven Community

NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

2 days ago - GlobeNewsWire

Arvinas to Present at Bank of America Securities Precision Oncology Conference

NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

6 days ago - GlobeNewsWire

hC Bioscience Appoints Brad Margus to its Board of Directors

CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- hC Bioscience, Inc., a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today...

2 weeks ago - GlobeNewsWire

Arvinas Announces Changes to its Board of Directors

NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

1 month ago - GlobeNewsWire

Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) --  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

1 month ago - GlobeNewsWire

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today report...

1 month ago - GlobeNewsWire

Arvinas Appoints John Northcott as Chief Commercial Officer

NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

2 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar?

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

3 months ago - Zacks Investment Research

Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announ...

4 months ago - GlobeNewsWire

Down 24% In A Month, Will Arvinas Stock Rebound?

The stock price of Arvinas (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, has fallen 24% in a month, while it's down a significant 49%...

4 months ago - Forbes

GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration

SOMERVILLE, Mass., May 9, 2022 /PRNewswire/ -- GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, today announced a collabo...

4 months ago - PRNewsWire

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -41.18% and 23.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reporte...

4 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Arvinas, Inc. (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Arvinas to Present at Upcoming Investor Conferences

NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou...

6 months ago - GlobeNewsWire

Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today report...

7 months ago - GlobeNewsWire

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Meta...

– Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA 50 rate and durable RECIST responses –

7 months ago - GlobeNewsWire

3 Stocks To Double Down On In 2022

The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination of the omicron fears, and the anticipation...

Other symbols: BBWIVTEX
7 months ago - Benzinga

Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer

BOSTON--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therape...

7 months ago - Business Wire

3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch

Is it time to buy a basket of biotech stocks?

Other symbols: KYMRPFE
7 months ago - The Motley Fool

Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients

Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with bavdegalutamide (ARV-110). The data were shared ...

7 months ago - Benzinga

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with No...

– Bavdegalutamide demonstrated a 46% PSA 50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations –

7 months ago - GlobeNewsWire

12 Super Small-Cap Stocks to Buy for 2022 and Beyond

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

8 months ago - Kiplinger